RELATIONSHIP BETWEEN SURGICAL PATHOLOGICAL RISK-FACTORS AND OUTCOME IN CLINICAL STAGE-I AND STAGE-II CARCINOMA OF THE ENDOMETRIUM - A GYNECOLOGIC ONCOLOGY GROUP-STUDY

被引:1127
作者
MORROW, CP
BUNDY, BN
KURMAN, RJ
CREASMAN, WT
HELLER, P
HOMESLEY, HD
GRAHAM, JE
机构
[1] UNIV SO CALIF,SCH MED,DIV GYNECOL ONCOL,LOS ANGELES,CA 90033
[2] NEW YORK STATE DEPT HLTH,ROSWELL PK MEM INST,BUFFALO,NY 14263
[3] JOHNS HOPKINS MED INST,BALTIMORE,MD 21205
[4] MED UNIV S CAROLINA,DEPT OBSTET & GYNECOL,CHARLESTON,SC 29425
[5] UNIV PENN,SCH MED,DEPT OBSTET & GYNECOL,PHILADELPHIA,PA 19104
[6] WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT OBSTET & GYNECOL,WINSTON SALEM,NC 27103
[7] RUSH PRESBYTERIAN ST LUKES MED CTR,DIV GYNECOL ONCOL,CHICAGO,IL 60612
关键词
D O I
10.1016/0090-8258(91)90086-K
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Between June 20, 1977 and February 5, 1983, the Gynecologic Oncology Group entered 1180 women with clinical stage I or II (occult) endometrial carcinoma into a surgical-pathological staging study. Eight hundred ninety-five patients with endometrioid or adenosquamous carcinoma were evaluable for this study which relates surgical-pathological parameters and postoperative treatment to recurrence-free interval and recurrence site. Proportional hazards modeling of time to recurrence was performed. For patients without metastasis determined by surgical-pathological staging the greatest determinant of recurrence was grade 3 histology [adenocarcinoma grade 3, relative risk (RR) = 15; adenosquamous carcinoma grade 3, RR = 8.1; all adenocanthomas, RR = 1.0). Of 48 patients with histologically documented aortic node metastases, 47 had one or more of the following features: (1) grossly positive pelvic nodes, (2) grossly positive adnexal metastasis, or (3) outer one-third myometrial invasion. Pelvic radiation was administered to 48.0% and vaginal brachytherapy alone to 10.2% of patients postoperatively; 41.8% received no adjuvant radiation therapy. None of three recurrences in the vaginal implant group were vaginal or pelvic; 7.4% (7 of 95) of recurrences in the pelvic radiation therapy (RT) group were vaginal and 16.8% were pelvic; 18.2% (8 of 44) of recurrences in the no adjuvant radiation group were vaginal and 31.8% pelvic. Because of the high degree of selection bias no valid comparisons can be made of recurrence-free interval in these groups. The 5-year recurrence-free interval for patients with negative surgical-pathological risk factors (other than grade and myoinvasion) was 92.7%; involvement of the isthmus/cervix 69.8%; positive pelvic cytology 56.0%; vascular space invasion 55.0%; pelvic node or adnexal metastases 57.8%; and aortic node metastases or gross laparotomy findings 41.2%. It is not clear that cervix invasion per se diminishes survival, because it is more often associated with poor tumor differentiation (34.7% versus 24.0%, grade 3) and deep myoinvasion (47.0% vs 18.6%) than cases without cervix invasion. The relapse rate among cervix-positive and -negative cases with grade 3 lesions and deep myoinvasion is not dramatically different (48.8% vs 39.8%). The proportion of failures which were vaginal/pelvic (34.6% for the surgery only group compared to 12.5% of the RT group) appears to favor the use of adjuvant radiation for patients with more than one-third myoinvasion and grade 2 or 3 tumor. There were 97 patients in the study group with malignant cytology of which 29.1% had regional/distant failure, which compares to 10.5% of the cytology-negative patients. These data seem to implicate malignant cytology as a serious adverse finding, especially with respect to the risk for regional/distant and abdominal failure. © 1991.
引用
收藏
页码:55 / 65
页数:11
相关论文
共 17 条
[1]  
BORONOW RC, 1984, OBSTET GYNECOL, V63, P825
[2]  
BORONOW RC, 1968, CANCER UTERUS TUBES, P36
[3]  
CREASMAN WT, 1987, CANCER, V60, P2035, DOI 10.1002/1097-0142(19901015)60:8+<2035::AID-CNCR2820601515>3.0.CO
[4]  
2-8
[5]  
Dobbie B M, 1965, J Obstet Gynaecol Br Commonw, V72, P659
[6]  
HAWKSWORTH W, 1964, P ROY SOC MED, V57, P467, DOI 10.1177/003591576405700611
[7]  
KOTTMEIER HL, 1968, CANCER UTERUS TUBES, P102
[8]  
LEES D H, 1969, Journal of Obstetrics and Gynaecology of the British Commonwealth, V76, P615
[9]  
LEFEVRE H, 1956, SURG GYNECOL OBSTET, V102, P649
[10]  
LEWIS B V, 1970, Journal of Obstetrics and Gynaecology of the British Commonwealth, V77, P343